UCB reports positive Week 24 data for BIMZELX from BE BOLD study

UCB announced new data from the BE BOLD study showing BIMZELX (bimekizumab-bkzx) maintained clinical improvements in patients through Week 24, building on earlier Week 16 findings that showed superior joint responses versus risankizumab.

Detected & updated continuously · Source: Nebula